Home
中文
取消
Sperogenix
Sperogenix Therapeutics is a platform focusing on development and commercialization of Rare Diseases Medications in China , provide clinically accessible products for rare disease patients and successful commercial solutions for rare disease therapeutics in China.
Focus on Four Diseases Areas
Pulmonary Vascular Diseases
Neurological Diseases
Inherited Metabolic Diseases
Non-Onco Hematologic Diseases
Patients
Empowering Patients Communities

Patient-Centric and empowering patients communities

Pay attention to different aspects of patients' needs, and meet the challenges of diagnosis, treatment, rehabilitation and payment together with patients.

Supporting capacity building and resources linkage for patient groups, promoting sustainable development of patient organizations.

more
News
2024-07-23 18:12:52
Company
Sperogenix Announces NDA of AGAMREE was Accepted in Hong Kong, China
July 23, 2024, Sperogenix Therapeutics announces the NDA filling of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) patients has been accepted by the Department of Health of Hong Kong, China.
2024-06-4 14:53:12
Company
First Chinese Patient was Treated with AGAMREE in Bo’ao Lecheng Pilot Zone
May 26, 2024, Sperogenix Therapeutics announced AGAMREE® (vamorolone) was introduced to the Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone.
2024-03-26 18:26:37
Company
NDA of AGAMREE was Accepted and Granted Priority Review by China’s CDE
March 26, 2024, the NDA filling of AGAMREE (vamorolone) is indicated for the treatment of DMD in patients aged 4 years and older has been accepted by CDE of China NMPA, and been included in the “Priority Review Program.
more